In recent years, large pharmaceutical companies have increased their investment in early research and development of anticancer drugs, mainly focusing on targeting, small molecules and biological agents. However, the success rate of new product research and development is only about 2%, and the average research and development cost exceeds 700 million US dollars. After a company goes public, it needs to recover its upfront investment through high pricing. Most of these anticancer drugs are patents and exclusive varieties, which lack market competition, have a large demand for clinical rigidity, and the bargaining power of medical institutions is insufficient, so it is difficult to effectively reduce prices.
-Limited support capacity
Limited by the level of economic development, the financing standard of basic medical insurance for urban and rural residents is not enough in 700 yuan, and the level of protection is low; After reimbursement of serious illness insurance, the burden of some patients at their own expense is still heavy; Supplementary insurance, commercial insurance, charity assistance, etc. Did not play a sufficient role; Coupled with the principle of fairness and economy, it is difficult to fully take care of the personalized medication needs of some cancer patients.
-unbalanced diagnosis and treatment ability
There is a shortage of high-quality resources for tumor treatment, and the service ability is quite different. The diagnosis, treatment mode selection and application of new technologies are not standardized, and pharmaceutical services such as drug treatment management need to be strengthened. In addition, cancer patients are often eager to seek medical treatment, repeat diagnosis and treatment, transfer to hospitals many times, and seek medical treatment in different places, which increases the economic burden.
-Prolonged survival time with tumor.
With the development of tumor prevention and treatment technology, the speed of listing new drugs is accelerated and the curative effect is improved. It can control the disease for a long time, maintain high-quality survival, bring good news to patients, and objectively increase the cost.
National Health Commission said that in order to make people use high-quality and low-priced drugs, according to the deployment of the State Council, the former National Health and Family Planning Commission and Ministry of Human Resources and Social Security have organized national drug price negotiations and national medical insurance catalogue negotiations respectively since 20 16, and the average price of 39 negotiated varieties has been reduced by more than 50%, which is at the global low price level.